Physician profile
John O Phillips
NPI 1023077732
$149,806.07
in general payments reported to CMS, 2019-2025
38 companies · $54K in 2025
The $54K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,410 · 2020: $6,522 · 2021: $3,464 · 2022: $15K · 2023: $22K · 2024: $38K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Food and Beverage: $8,886 · Travel and Lodging: $5,766 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,189.50 |
| Food and Beverage | $8,885.50 |
| Travel and Lodging | $5,766.30 |
| Education | $117.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $94,588.67 | 2019-2025 | Epclusa, Livdelzi |
| Madrigal Pharmaceuticals | $29,785.83 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $11,141.45 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $7,498.05 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,619.37 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $782.57 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $553.24 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $422.71 | 2022-2025 | |
| Intra-Sana Laboratories | $357.08 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Janssen Biotech, INC. | $340.88 | 2019-2025 | Stelara, Tremfya, Simponi |
| Phathom Pharmaceuticals, INC. | $310.65 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $276.81 | 2022-2025 | Sucraid, Sucraid |
| Mallinckrodt Hospital Products INC. | $192.69 | 2021-2023 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $185.10 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $177.09 | 2023-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $173.72 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $169.88 | 2019-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $155.81 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $140.19 | 2021-2023 | |
| Celgene Corporation | $111.41 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $109.78 | 2022 | |
| Aimmune Therapeutics, INC. | $101.45 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $99.55 | 2022-2025 | Sutab, Suflave |
| Boston Scientific Corporation | $91.05 | 2021-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Resolution 360 Ultra Clip, Watchman Flx |
| Dova Pharmaceuticals | $59.51 | 2019 | |
| Pfizer INC. | $57.58 | 2019-2023 | |
| Fresenius Kabi USA, LLC | $53.33 | 2023 | Idacio |
| Celltrion USA INC. | $42.56 | 2024 | Zymfentra |
| Biocompatibles, INC. | $41.88 | 2019 | |
| Enterra Medical, INC. | $41.51 | 2022-2023 | |
| Amgen INC. | $39.78 | 2025 | Uplizna |
| Lilly USA, LLC | $33.84 | 2023-2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $19.06 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.97 | 2022 | |
| Medtronic, INC. | $11.68 | 2022 | |
| Organon LLC | $5.34 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.